C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids
暂无分享,去创建一个
J. Witztum | C. Binder | M. Torzewski | Joseph L. Witztum | Mi-Kyung Chang | Mi-Kyung Chang | Christoph J. Binder | Michael Torzewski
[1] N. Sigal,et al. The frequency of phosphorylcholine-specific B cells in conventional and germfree BALB/C mice. , 1975, Journal of immunology.
[2] C. Mold,et al. Serum Amyloid P Component and C-Reactive Protein Mediate Phagocytosis Through Murine FcγRs1 , 2001, The Journal of Immunology.
[3] E. Dennis,et al. The Binding of Oxidized Low Density Lipoprotein to Mouse CD36 Is Mediated in Part by Oxidized Phospholipids That Are Associated with Both the Lipid and Protein Moieties of the Lipoprotein* , 2000, The Journal of Biological Chemistry.
[4] T. D. Du Clos,et al. C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. , 1989, Journal of immunology.
[5] I. Tabas,et al. Nonoxidative modifications of lipoproteins in atherogenesis. , 1999, Annual review of nutrition.
[6] J. Volanakis,et al. Human C-reactive protein: expression, structure, and function. , 2001, Molecular immunology.
[7] D. Shih,et al. Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis* , 2000, The Journal of Biological Chemistry.
[8] R. Murphy,et al. Bioactive phospholipid oxidation products. , 2000, Free radical biology & medicine.
[9] V. Hombach,et al. C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages: Implications for Atherosclerosis , 2001, Circulation.
[10] J. Witztum,et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. , 1996, The Journal of clinical investigation.
[11] B. Binder,et al. Oxidized Membrane Vesicles and Blebs From Apoptotic Cells Contain Biologically Active Oxidized Phospholipids That Induce Monocyte‐Endothelial Interactions , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[12] N. Brot,et al. C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response , 2000, The Journal of experimental medicine.
[13] Charles A. Janeway,et al. Decoding the Patterns of Self and Nonself by the Innate Immune System , 2002, Science.
[14] J. Berliner,et al. Evidence for a role of phospholipid oxidation products in atherogenesis. , 2001, Trends in cardiovascular medicine.
[15] G. Silverman,et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. , 2000, The Journal of clinical investigation.
[16] W. Koenig,et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[17] K. Wirtz,et al. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers , 1979, Nature.
[18] C. Mold,et al. Regulation of complement activation by C-reactive protein. , 1999, Immunopharmacology.
[19] D. Steinberg,et al. Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. , 2001, Journal of lipid research.
[20] E. Dennis,et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Kearney. Immune recognition of OxLDL in atherosclerosis. , 2000, The Journal of clinical investigation.
[22] T. D. Du Clos,et al. Analysis of the binding of C-reactive protein to histones and chromatin. , 1988, Journal of immunology.
[23] H. Gabbert,et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[24] P. Ridker,et al. Novel clinical markers of vascular wall inflammation. , 2001, Circulation research.
[25] J L Witztum,et al. Oxidized phospholipids and isoprostanes in atherosclerosis. , 1998, Current opinion in lipidology.
[26] M. H. Kaplan,et al. Studies of acute phase protein. I. An immunohistochemical method for the localization of Cx-reactive protein in rabbits. Association with necrosis in local inflammatory lesions. , 1961 .
[27] D. Bharadwaj,et al. The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II , 1999 .
[28] E. Dennis,et al. Correlation of Antiphospholipid Antibody Recognition with the Structure of Synthetic Oxidized Phospholipids , 2002, The Journal of Biological Chemistry.
[29] E. Dennis,et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. , 1999, The Journal of clinical investigation.
[30] T. Kodama,et al. Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system , 1998, Cellular and Molecular Life Sciences CMLS.
[31] G. Zimmerman,et al. Oxidized LDL contains inflammatory PAF-like phospholipids. , 2001, Trends in cardiovascular medicine.
[32] J. Volanakis,et al. C‐REACTIVE PROTEIN BINDING SPECIFICITIES: ARTIFICIAL AND NATURAL PHOSPHOLIPID BILAYERS * , 1982, Annals of the New York Academy of Sciences.
[33] S. Bhakdi,et al. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[34] A. Feinstein,et al. Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins , 1984, The Journal of experimental medicine.
[35] P. Libby,et al. Inflammation and Atherosclerosis , 2002, Circulation.
[36] D. Steinberg,et al. Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[37] T. Kodama,et al. Protection from Lethal Gram-Positive Infection by Macrophage Scavenger Receptor–Dependent Phagocytosis , 2000, The Journal of experimental medicine.
[38] R. Ross,et al. Atherosclerosis is an inflammatory disease. , 1998, American heart journal.
[39] Christopher K. Glass,et al. Atherosclerosis The Road Ahead , 2001, Cell.
[40] R. Terkeltaub,et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. , 1996, The Journal of clinical investigation.